Fluoroquinolone resistance in Mycobacterium tuberculosis: An assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1173-1178

  Devasia, Rose A ^a   Blackman, Amondrea ^a   May, Carolyn ^a   Eden, Svetlana ^a   Smith, Teresa ^b   Hooper, Nancy ^c   Maruri, Fernanda ^a   Stratton, Charles ^a   Shintani, Ayumi ^a   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

^c Maryland State Laboratory   (United States)

Author keywords

Fluoroquinolones; Susceptibility tests; Tuberculosis

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NITRATE REDUCTASE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR MEDIUM; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; HUMAN; INTERMETHOD COMPARISON; MICROSCOPIC OBSERVATION DRUG SUSCEPTIBILITY ASSAY; MYCOBACTERIUM GROWTH INDICATOR TUBE 960; MYCOBACTERIUM TUBERCULOSIS; NITRATE REDUCTASE ASSAY; SENSITIVITY AND SPECIFICITY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NITRATE REDUCTASE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 65749102080     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp096     Document Type: Article

References (34)

1. Kruijshaar ME, Watson JM, Drobniewski F et al. Increasing antituberculosis drug resistance in the United Kingdom: Analysis of National Surveillance Data. BMJ 2008; 336: 1231-4.
2. Aziz MA, Wright A, Laszlo A et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): An updated analysis. Lancet 2006; 368: 2142-54.
3. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
4. Narayanan P. Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002; 49: 27-38.
5. Chaisson RE, Conde M, Efron A et al. A randomized placebo-controlled trial of moxifloxacin vs. ethambutol in the initial phase of tuberculosis therapy in Brazil. In: Final Program of the Forty-seventh Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract L-736a, p. 221. American Society for Microbiology, Washington, DC, USA.
6. Berlin OG, Young LS, Bruckner DA. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 611-5.
7. Hoffner SE, Gezelius L, Olsson-Liljequist B. In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885-8.
8. Rodriguez JC, Ruiz M, Climent A et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17: 229-31.
9. Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-38.
10. WHO. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: World Health Organization, 2008. WHO/HTM/TB/ 2004.402.
11. Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-81.
12. Mitnick CD, Shin SS, Seung KJ et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359 563-74.
13. Dong Y, Xu C, Zhao X et al. Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998; 42: 2978-84.
14. Zhao BY, Pine R, Domagala J et al. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999; 43: 661-6.
15. Somasundaram S, Paramasivan NC. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 2006; 52: 190-5.
16. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M-24A. NCCLS, Wayne, PA, USA, 2003.
17. Devasia R, Griffin M, Blackman A et al. Trends in fluoroquinolone resistance and exposure in newly diagnosed tuberculosis: 2002-06. Am J Respir Crit Care Med 2008; 177: A19.
18. Palaci M, Ueki S, Sato D et al. Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens. J Clin Microbiol 1996; 34: 762-4.
19. Rusch-Gerdes S, Pfyffer G, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
20. Martin A, Palomino J, Portaels F. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: Resazurin and nitrate reductase assays. J Clin Microbiol 2005; 43: 1612-6.
21. Piersimoni C, Lacchini C, Penati V et al. Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin. Diagn Microbiol Infect Dis 2007; 57: 283-87.
22. Kruuner A, Yates M, Drobniewski F. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-8.
23. Sanders C, Nieda R, Desmond E. Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J Clin Microbiol 2004; 42: 5225-8.
24. BD Bactec MGIT 960 AST Instructions. Sparks, Maryland, Document MA-0126 Revision E.
25. Caviedes L, Lee T, Gilman R et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol 2000; 38: 1203-8.
26. Angeby K, Klintz L, Hoffner S. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol 2002; 40: 553-5.
27. Poojary A, Nataraj G, Kanade S et al. Rapid antibiotic susceptibility testing of Mycobacterium tuberculosis: Its utility in resource poor settings. Indian J Med Microbiol 2006; 24: 268-72.
28. Wilson E. Probable inference, the law of succession, and statistical inference. JASA 1927; 22: 202-12.
29. Harrel F. Harrel Miscellaneous. R package version 3.0-12. 2006.
30. R Developmental Core Team. R: A Language and Environment for Statistical Computing. Free open source statistical software available at http://www.R-project.org (23 March 2009, date last accessed).
31. Global Business Coalition: Awards for Business Excellence. http://www.finddiagnostics.org/news/gbc_awards_jun08.pdf (19 February 2009, date last accessed).
32. Moore D, Evans C, Gilman R et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-50.
33. Syre H, Phyu S, Sandven P et al. Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures. J Clin Microbiol 2003; 41: 5173-7.
34. Montoro E, Lemus D, Echemendia M et al. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2005; 55: 500-5.